ClinicalTrials.gg
RecruitingNCT07528209Updated Apr 30, 2026

Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer

A Phase 3 interventional study of Pucotenlimab combine with CAPOX and CAPOX in Rectal Cancer and pMMR (Microsatellite Stable Rectal Cancer), sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
556
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies in Rectal Neoplasms by Sun Yat-sen University — 19 open to participants now, 24 under way, 6 of them phase 3. Rectal Neoplasms · Sun Yat-sen University.

Planned enrollment
6th of 31
556 · median 100
Started
2026
with 2 others
Phase 3
6 of 39
4 open now
Primary completion
2032-04
later than 23 of 23 live
Registered
36th of 39
by date

Among the 39 studies in Rectal Neoplasms by Sun Yat-sen University, this one is the 6th largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 23 of the 23 other live ones, and was the 36th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

19 of the 39 studies in Rectal Neoplasms by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Rectal Neoplasms by Sun Yat-sen University, or all of them as a file.
02

Study summary

This is a multicenter, phase III, randomized controlled trial. Eligible patients with pMMR/MSS locally advanced rectal cancer will be randomized in a 1:1 ratio to either the experimental group or the control group using stratified randomization, with mesorectal fascia (MRF) status as the stratification factor.

Patients in the experimental group will receive four cycles of CAPOX plus pucotenlimab. Patients in the control group will receive four cycles of CAPOX alone.

Tumor response will then be assessed. Patients with tumor shrinkage ≥20% and no persistent tumor involvement of the mesorectal fascia will proceed directly to surgery. Patients with tumor shrinkage \<20% or persistent MRF-positive disease will receive short-course radiotherapy, followed by two additional cycles of CAPOX plus pucotenlimab in the experimental group or CAPOX alone in the control group. After completion of neoadjuvant treatment, efficacy will be reassessed, and the timing of surgery will be determined according to treatment response. Postoperative adjuvant therapy will be decided by the investigator.

Read the detailed description

Colorectal cancer (CRC) is the third most common malignancy worldwide. Rectal cancer accounts for more than half of CRC cases in many regions, making it a major clinical challenge. The standard treatment for locally advanced rectal cancer (LARC) includes neoadjuvant chemoradiotherapy, total mesorectal excision (TME), and postoperative adjuvant chemotherapy. However, distant metastasis and postoperative complications remain major challenges. Total neoadjuvant therapy (TNT), by advancing adjuvant chemotherapy to the neoadjuvant phase, has significantly improved patient compliance and tumor response rates. The MSKCC study demonstrated a tumor response rate of up to 90% under the TNT regimen, with 30% of patients achieving pathological or clinical complete response (pCR or cCR). The TIMING trial further confirmed that TNT significantly increased the pCR rate without increasing side effects or surgical complications.

Immunotherapy has shown significant efficacy in dMMR/MSI-H CRC. The NICHE study demonstrated that dual immunotherapy achieved 100% pathological response in dMMR colorectal cancer patients. However, pMMR/MSS CRC is not sensitive to immunotherapy, but some patients may still benefit from combined anti-angiogenesis agents (such as regorafenib) or CTLA-4 antibodies. The REGONIVO study showed an objective response rate (ORR) of 36.0% in pMMR/MSS CRC patients, while the RIN study further increased the ORR to 27.6%. Radiotherapy combined with immunotherapy has emerged as a new treatment modality for LARC. The UNION study found that short-term radiotherapy followed by sequential PD-1 antibody and CAPOX chemotherapy increased the pCR rate to 39.8%. The TORCH study explored the effectiveness of short-term radiotherapy combined with PD-1 antibody and CAPOX chemotherapy, achieving a CR rate of over 50%. The REGINA study went further, using short-term radiotherapy combined with regorafenib and nivolumab, achieving a CR rate of 44.4%.

Although radiotherapy improves local control, it may cause significant short- and long-term toxicities, such as radiation enteritis, cystitis, and impaired anorectal, urinary, and sexual function. It may also increase surgical complexity and reduce postoperative quality of life. These concerns have driven growing interest in radiotherapy decline or even omission in selected patients. Neoadjuvant chemotherapy alone has therefore been investigated as an alternative approach. Studies such as PROSPECT, FOWARC, and the CONVERT study from our center suggest that neoadjuvant chemotherapy alone does not increase local recurrence or distant metastasis in selected patients, while substantially reducing radiation-related toxicity. In particular, the CONVERT study demonstrated that among patients with high-resolution MRI-defined negative circumferential resection margin risk, neoadjuvant chemotherapy was not inferior to conventional chemoradiotherapy. These findings provide proof of concept for a selective radiotherapy strategy.

Based on this background, we propose the CONVERT-2 study, a multicenter phase III trial designed to evaluate neoadjuvant CAPOX plus pucotenlimab with selective radiotherapy versus CAPOX with selective radiotherapy in patients with pMMR/MSS locally advanced rectal cancer. We hypothesize that the addition of pucotenlimab will further increase tumor response, reduce the proportion of patients requiring radiotherapy, and maintain favorable safety and oncologic outcomes. If successful, this study may establish a more individualized neoadjuvant strategy for pMMR/MSS LARC, balancing treatment efficacy, toxicity reduction, and organ preservation.

03

Conditions studied

  • Rectal Cancer
  • pMMR (Microsatellite Stable Rectal Cancer)

Browse trials for

Keywords

  • Rectal cancer
  • Neoadjuvant Therapy
  • pMMR/MSS
  • Immunotherapy
  • Selective radiotherapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 75 years.
  2. confirmed rectal adenocarcinoma.
  3. The lower edge of the tumor is ≤12 cm from the anal verge.
  4. Clinical stage of cT3-4aN0M0 or cT1-4aN+M0 at initial diagnosis.

    Pre-treatment staging methods:

    Required: chest and abdominal CT and pelvic MRI. Optional: endorectal ultrasound or transrectal ultrasonography. For patients with to MRI, staging may be performed using CT combined with endorectal ultrasound or transrectal ultrasonography.

  5. pMMR status confirmed by immunohistochemistry on colonoscopic specimens at the pathology department of the study center, or MSS/MSI-L status confirmed by genetic testing (PCR-based or NGS-based methods).
  6. performance status 0-1.
  7. Voluntary participation in the study with written provided.
  8. No prior antitumor treatment for rectal adenocarcinoma, including but not limited to radiotherapy, chemotherapy, or surgery.
  9. Expected survival of at least 6 months.
  10. Adequate organ and bone marrow function, as defined below:

    1. Hematologic function No blood transfusion, hematopoietic growth factors, leukocyte-elevating agents, -elevating agents, or anti-anemia therapy are allowed within 14 days before the first dose of study treatment.

      ≥1.5 × 10\^9/L Platelet count ≥100 × 10\^9/L ≥60 g/L

    2. Biochemical function Serum albumin ≥30 g/L Total ≤1.5 × (ULN) ≤2.5 × ULN AST ≤2.5 × ULN Alkaline phosphatase (ALP) ≤2.5 × ULN Serum creatinine ≤1.5 × ULN, or (CrCl) ≥50 mL/min

CrCl may be calculated using the Cockcroft-Gault formula:

Male: CrCl = ((140-age)×weight)((140 - age) × weight)((140-age)×weight) / (72×serumcreatinine)(72 × serum creatinine)(72×serumcreatinine) Female: CrCl = ((140-age)×weight)((140 - age) × weight)((140-age)×weight) / (72×serumcreatinine)(72 × serum creatinine)(72×serumcreatinine) × 0.85 Weight in kg; serum creatinine in mg/mL. c. Coagulation function (INR) ≤1.5 d. Urinary protein Urine protein ≤1+ by dipstick If urine protein is ≥2+, a 24-hour urine protein test is required, and patients may be enrolled only if the result is \<1 g/24 h

  1. For women of , a serum or urine pregnancy test must be performed within 72 hours before the start of study treatment, with a negative result. Such patients must agree to use effective during the study and for at least 120 days after the last dose of study treatment.
  2. Good compliance and willingness to cooperate with study follow-up.
  3. Agreement to provide blood, urine, stool, and tumor tissue samples.

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded:

  1. Clinical stage T4b disease.
  2. Positive lateral pelvic lymph nodes.

Positive lateral pelvic lymph nodes are defined as either:

  1. a short-axis diameter ≥7 mm, or
  2. a short-axis diameter \<7 mm with at least two malignant imaging features, such as heterogeneous signal intensity, irregular shape, or spiculated margins.
  3. Predicted inability to preserve the anus. This is defined as tumor involvement of the dentate line and assessment by two senior colorectal surgeons that sphincter preservation is not feasible.
  4. Active disease requiring systemic treatment within 2 years before enrollment, including but not limited to myasthenia gravis, systemic lupus erythematosus, interstitial pneumonitis, uveitis, ulcerative colitis, autoimmune hepatitis, hypophysitis, systemic vasculitis, nephritis, hyperthyroidism, hypothyroidism, or mixed connective tissue disease.

    Patients with vitiligo or childhood asthma that has completely resolved and requires no intervention in adulthood may be eligible.

    Asthma requiring bronchodilator therapy is not allowed. Replacement therapy, such as thyroxine, insulin, or physiologic replacement for adrenal or pituitary insufficiency, is not considered systemic treatment.

  5. Use of systemic corticosteroids within 14 days before the first dose of study treatment at a dose ≥10 mg/day prednisone equivalent, or use of other agents, including but not limited to cyclosporine, cyclophosphamide, azathioprine, methotrexate, or thalidomide.

    Use of immunostimulatory agents such as interferon or interleukin-2 within 4 weeks before the first dose is also excluded.

  6. Receipt of a or attenuated live vaccine within 30 days before the first dose, or planned vaccination with such vaccines during the study period.
  7. Broad-spectrum antibiotic therapy by any route within 30 days before the first dose.
  8. Prior antitumor therapy for rectal cancer, including radiotherapy, chemotherapy, surgery (except ), /CTLA-4 dual immunotherapy, regorafenib, or any other tyrosine kinase inhibitor.
  9. Presence of unresectable disease, including tumor-related unresectability, unresectability due to surgical , or refusal to undergo surgery.
  10. infection, other acquired or congenital immunodeficiency disorders, or a history of organ transplantation or bone marrow transplantation (except corneal transplantation).
  11. Active viral hepatitis meeting any of the following criteria:

    surface antigen (HBsAg) positive and/or hepatitis B core antibody (HBcAb) positive with HBV DNA >10\^4 copies/mL (approximately 2000 IU/mL) anti- antibody positive with HCV RNA >10\^3 copies/mL concurrent HBV and HCV infection, defined as HBsAg positive and HCV RNA positive

  12. History of other within the past 5 years or concurrent malignancy, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix.
  13. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage.
  14. Known active tuberculosis, radiation pneumonitis, drug-induced pneumonitis, or other diseases, symptoms, or signs indicating severely impaired pulmonary function.
  15. Renal failure requiring hemodialysis or peritoneal dialysis.
  16. Active infection, unexplained fever ≥38.5°C within 7 days before treatment, or baseline white blood cell count >15 × 10\^9/L.
  17. Uncontrolled cardiac disease, including but not limited to:

    (NYHA) class II or above heart failure (LVEF) \<50% unstable angina myocardial infarction within 1 year before randomization clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention interval (QTc) >450 ms in males or >470 ms in females

  18. Hypertension not adequately controlled with antihypertensive treatment, defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.

    Patients whose blood pressure can be controlled to below these thresholds with treatment are eligible.

    A history of hypertensive crisis or hypertensive encephalopathy is excluded.

  19. Arterial or venous thrombotic events within 6 months before enrollment, including cerebrovascular accident, , cerebral hemorrhage, cerebral infarction, deep venous thrombosis, or pulmonary embolism.
  20. Known hereditary or acquired bleeding or thrombotic disorders, such as hemophilia or coagulation dysfunction.
  21. Tumor invasion of major blood vessels, or imaging findings suggesting a high likelihood of major vascular invasion during the study period that may result in fatal hemorrhage, as judged by the investigator.
  22. Major surgery (excluding diagnostic procedures) within 4 weeks before the start of study treatment, or an anticipated need for major surgery during the study period other than protocol-specified surgery.
  23. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months before the start of study treatment.
  24. Need for long-term or high-dose nonsteroidal anti-inflammatory drugs (for example, aspirin ≥325 mg/day) or anticoagulant therapy.
  25. Known or suspected allergy to the study drugs or to any medications administered in relation to this trial.
  26. History of severe reactions to other monoclonal antibodies, or known allergy or hypersensitivity to PD-1 antibodies, oxaliplatin, capecitabine, or any of their components.
  27. Difficulty swallowing or inability to take oral study medication.
  28. Pregnant or breastfeeding women.
  29. Any other condition that, in the investigator's judgment, may interfere with study participation, affect study results, increase patient risk, or lead to premature termination of the study, including but not limited to alcohol abuse, drug abuse, severe comorbidities (including psychiatric disorders), significant laboratory abnormalities, or family/social factors affecting patient safety or compliance.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
556 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Patients in the experimental group will receive four cycles of CAPOX plus pucotenlimab. Tumor response will then be assessed. Patients with tumor shrinkage ≥20% and no persistent tumor involvement of the mesorectal fascia will proceed directly to surgery. Patients with tumor shrinkage \<20% or persistent MRF-positive disease will receive short-course radiotherapy, followed by two additional cycles of CAPOX plus pucotenlimab in the experimental group . After completion of neoadjuvant treatment, efficacy will be reassessed, and the timing of surgery will be determined according to treatment response. Postoperative adjuvant therapy will be decided by the investigator.

    Drug: CAPOX

  • Active comparator
    Control group

    Patients in the control group will receive four cycles of CAPOX alone. Tumor response will then be assessed. Patients with tumor shrinkage ≥20% and no persistent tumor involvement of the mesorectal fascia will proceed directly to surgery. Patients with tumor shrinkage \<20% or persistent MRF-positive disease will receive short-course radiotherapy, followed by two additional cycles of CAPOX alone in the control group. After completion of neoadjuvant treatment, efficacy will be reassessed, and the timing of surgery will be determined according to treatment response. Postoperative adjuvant therapy will be decided by the investigator.

    Drug: Pucotenlimab combine with CAPOX

Interventions

  • DrugPucotenlimab combine with CAPOX

    Pucotenlimab will be administered at 200 mg intravenously on Day 1 every 3 weeks. Oxaliplatin will be administered at 130 mg/m² intravenously over more than 2 hours on Day 1 every 3 weeks. Capecitabine will be administered orally at 1000 mg/m² twice daily on Days 1 through 14 every 3 weeks. Patients in the experimental group will receive four cycles of CAPOX plus pucotenlimab. Tumor response will then be assessed. Patients with tumor shrinkage ≥20% and no persistent tumor involvement of the mesorectal fascia will proceed directly to surgery. Patients with tumor shrinkage \<20% or persistent MRF-positive disease will receive short-course radiotherapy, followed by two additional cycles of CAPOX plus pucotenlimab in the experimental group . After completion of neoadjuvant treatment, efficacy will be reassessed, and the timing of surgery will be determined according to treatment response. Postoperative adjuvant therapy will be decided by the investigator.

  • DrugCAPOX

    Oxaliplatin will be administered at 130 mg/m² intravenously over more than 2 hours on Day 1 every 3 weeks. Capecitabine will be administered orally at 1000 mg/m² twice daily on Days 1 through 14 every 3 weeks. Patients in the control group will receive four cycles of CAPOX alone. Tumor response will then be assessed. Patients with tumor shrinkage ≥20% and no persistent tumor involvement of the mesorectal fascia will proceed directly to surgery. Patients with tumor shrinkage \<20% or persistent MRF-positive disease will receive short-course radiotherapy, followed by two additional cycles of CAPOX alone in the control group. After completion of neoadjuvant treatment, efficacy will be reassessed, and the timing of surgery will be determined according to treatment response. Postoperative adjuvant therapy will be decided by the investigator.

06

What researchers measure

Primary outcomes

  1. 3-year disease-free survival (DFS) rate

    DFS is defined for patients who are disease-free after surgery as the time from the postoperative baseline imaging assessment to the first occurrence of local recurrence, distant recurrence, or death from any cause, whichever occurs first.

    Time frame: 3 year

Secondary outcomes

  1. Complete response (CR) rate

    Defined as the proportion of patients achieving either clinical complete response (cCR) or pathological complete response (pCR).

    Time frame: At completion of neoadjuvant treatment and surgery assessment

  2. Objective response rate (ORR)

    Defined as the proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST version 1.1.

    Time frame: At completion of neoadjuvant treatment and surgery assessment

  3. R0 resection rate

    Defined as the proportion of patients undergoing surgery who achieve R0 resection.

    Time frame: At completion of neoadjuvant treatment and surgery assessment

  4. Rate of radiotherapy use

    Defined as the proportion of patients who receive radiotherapy during neoadjuvant treatment.

    Time frame: At completion of neoadjuvant treatment and surgery assessment

  5. Major pathological response (MPR) rate

    Defined as the proportion of patients with ≤10% residual viable tumor in the primary tumor.

    Time frame: At completion of neoadjuvant treatment and surgery assessment

  6. Tumor Regression Grade (TRG)

    Assessed according to the AJCC 8th edition staging system.

    Time frame: At completion of neoadjuvant treatment and surgery assessment

  7. 5-year overall survival (OS) rate

    The time interval between the date of randomization to the date of death. If the patient has been alive, the time until the last follow-up is taken as the overall survival period.

    Time frame: 5 years

  8. Anal function assessed by the Wexner score

    Used to assess anal function.

    Time frame: From surgery to 3 years after surgery

  9. Quality of Life Score

    Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The scale score ranges from 0 to 100. For global health status and functional scales, higher scores indicate better quality of life or functioning. For symptom scales/items, higher scores indicate a higher symptom burden or worse quality of life.

    Time frame: 5 years

  10. Incidence of adverse events

    Assessed by Common Terminology Criteria for Adverse Events version 4.0. The overall adverse event rates and the immune-related adverse event rates will be compared between treatment arms using Chi-square test or Fisher's exact test, as appropriate.

    Time frame: up to 30 days after last treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2032, 72 months later.

Of 73 non-industry phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 104. This study's planned 72 months is close to that.

Counting every sponsor, half of 81 studies reached it within 59 months; a quarter within 37 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 14, 2026
StartEst.
Apr 20, 2026
Primary completionEst.
Apr 20, 2032
CompletionEst.
Apr 20, 2034
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07528209
Responsible party
Pei-Rong Ding (Director of the Department of Colorectal Surgery, Sun Yat-sen University) — Principal investigator
First posted
Apr 14, 2026
Start date
Apr 20, 2026 (estimated)
Primary completion
Apr 20, 2032 (estimated)
Completion
Apr 20, 2034 (estimated)
Last update
Apr 30, 2026

Study contacts

Kai Han, M.D
Contact
hankai@sysucc.org.cn
+86-18602042643
Peirong Ding, M.D.
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion